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Abstract PDC-109, the major heparin-binding protein of bull
seminal plasma, binds to sperm choline lipids at ejaculation and
modulates capacitation mediated by heparin. Affinity chroma-
tography on heparin-Sepharose showed that polydisperse, but not
monomeric, PDC-109 displayed heparin-binding capability. We
sought to characterise the surface topology of the quaternary
structure-dependent heparin-binding region of PDC-109 by
comparing the arginine- and lysine-selective chemical modifica-
tion patterns of the free and the heparin-bound protein. A
combination of reversed-phase peptide mapping of endoprotein-
ase Lys-C-digested PDC-109 derivatives and mass spectrometry
was employed to identify modified and heparin-protected
residues. PDC-109 contains two tandemly arranged fibronectin
type II domains (a, Cys24-Cys61 ; b, Cys69-Cys109). The results
show that six basic residues (Lys34, Arg57, Lys59, Arg64, Lys68,
and Arg104) were shielded from reaction with acetic anhydride
and 1,2-cyclohexanedione in heparin-bound PDC-109 oligomers.
In the 1H-NMR solution structures of single fibronectin type II
domains, residues topologically equivalent to PDC-109 Arg57
(Arg104) and Lys59 lay around L-strand D on the same face of
the domain. In full-length PDC-109, Arg64 and Lys68 are both
located in the intervening polypeptide between domains a and b.
Our data suggest possible quaternary structure arrangements of
PDC-109 molecules to form a heparin-binding oligomer.
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1. Introduction
Studies on mammalian reproductive physiology established
that spermatozoa leaving the testis appear mature from a
morphological standpoint but are unable to fertilise a meta-
phase II-arrested egg [1]. They gain their full fertilising ca-
pacity upon residence for a de¢ned period of time in the
female fallopian tube owing to a process termed capacitation.
Although capacitation was discovered nearly half a century
ago [2^5], the molecular and physiological bases of this event
are still poorly understood. Ultrastructural and biochemical
studies suggest that spermatozoa undergoing capacitation ex-
hibit a membrane-remodelling process, including decrease in
the molar ratio of cholesterol to phospholipids (membrane
£uidity changes) and modi¢cation of the chemical and topo-
graphical composition of integral and peripherally bound
membrane components [1,6,7].
Reports from several species indicate that the seminal plas-
ma, the mixed secretions of the male accessory reproductive
organs in which spermatozoa are suspended in semen, con-
tains factors that in£uence the fertilising ability of spermato-
zoa. In the bull, Miller and co-workers [8] demonstrated a
positive regulatory role of seminal plasma heparin-binding
proteins in the in vitro capacitation of bull sperm. Acidic
proteins PDC-109 (also termed BSP-A1/A2), BSP-A3, and
BSP-30K, are secreted by the seminal vesicle epithelium and
constitute the major heparin-binding proteins of bull seminal
plasma [9^11]. PDC-109 and BSP-A3 bind speci¢cally to chol-
ine phospholipids [12^14], mainly on the sperm head posta-
crosomal surface [15]. BSP-30K also binds to choline phos-
pholipids but displays a much broader speci¢city [12]. Isolated
PDC-109, BSP-A3, and BSP-30K each potentiate in vitro
zona pellucida-induced acrosome reactions in the presence
of heparin [16]. In addition to heparin, the bovine seminal
plasma (BSP) proteins interact with a variety of ligands in-
cluding di¡erent types of collagen, ¢brinogen, apolipoprotein
A1 (apoA1) and apoA1/high-density lipoprotein (HDL) com-
plexes [16]. It has been proposed [13^15] that upon binding to
sperm surface choline lipids, which comprise over 70% of the
total bull sperm plasma membrane phospholipids [17], mod-
i¢cation of the sperm plasma membrane composition by BSP
proteins may underlie modulation of capacitation by HDL
and heparin-like glycosaminoglycans that are present in the
follicular and oviductal £uids of the cow at particularly high
concentrations during the oestrus cycle [18].
PDC-109, a 109-amino acid residue polypeptide, is the most
abundant protein of bull (Bos taurus) seminal plasma, where
its concentration reaches 15^20 mg/ml [19]. PDC-109 coats to
the sperm surface at ejaculation and around 8 million PDC-
109 have been quantitated on the surface of a single bull
spermatozoon after incubation for 24 h in capacitation me-
dium [19]. Structurally, PDC-109 belongs to the same protein
family as BSP-A3 and BSP-30K. Each of these proteins dis-
plays a mosaic architecture, which consists of N-terminal dis-
tinctly O-glycosylated polypeptide extensions of variable
length followed by two tandemly arranged and highly con-
served ¢bronectin type II domains ([11] and references there-
in). Glycoprotein PDC-109 has been crystallised in complex
with o-phosphorylcholine (oPC) [20]. The resolution of the
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crystal structure of the PDC-109/oPC complex will serve to
model the binding mechanism of the seminal plasma protein
to sperm choline lipids. Here, we show that heparin binding
by PDC-109 is dependent on its aggregation state. A heparin
protection assay and selective chemical modi¢cation in com-
bination with peptide mapping and mass spectrometry were
applied for the identi¢cation of basic residues of PDC-109
forming part of its conformational heparin-binding region.
2. Materials and methods
2.1. Isolation and characterisation of PDC-109
PDC-109 was puri¢ed from the seminal plasma of healthy and
reproductively active Holstein bulls (a generous gift of Rinder Pro-
duktion Niedersachsen, Verden, Germany) by a⁄nity chromatogra-
phy as previously described [21]. Isolated PDC-109 was pure as
judged by SDS-polyacrylamide electrophoresis, N-terminal sequence
analysis (using an Applied Biosystems Procise instrument), and ma-
trix-assisted laser-desorption ionisation (MALDI) mass spectrometry
(using a Kratos MALDI-I spectrometer and 3,5-dimethoxy-4-hydrox-
ycinnamic acid (Aldrich) saturated in 2:1 (v/v) acetonitrile/0.1% tri-
£uoroacetic acid as matrix) [19,21]. It consisted of a roughly equimo-
lar mixture of non-glycosylated (12 788 Da) and O-glycosylated
(13 443 Da) [19,22] molecules.
2.2. A⁄nity chromatography
5 mg of isolated PDC-109 in 50 mM Tris-HCl, pH 7.4, was bound
at room temperature to a 5 ml heparin-Sepharose (Pharmacia) column
equilibrated in this bu¡er. In successive experiments, the protein was
eluted with gradients of column bu¡er (solution A) and column bu¡er
containing either 150 mM ortho-phosphorylcholine, 150 mM EDTA,
125 mM CaCl2, and 350 mM NaCl.
2.3. Selective chemical modi¢cation of arginine residues and amino
groups
PDC-109 (V1 mg/ml in 16.6 mM Tris-HCl, 50 mM NaCl, 1.6 mM
EDTA, 0.025% NaN3, pH 7.4) was applied to 5 ml heparin-Sepharose
(Pharmacia) equilibrated in the same bu¡er. After washing out un-
bound material, the column was recycled overnight at room temper-
ature with either 1,2-cyclohexanedione (0.04^6-fold molar excess over
arginine residues) or acetic anhydride (25^1600-fold molar excess over
lysine residues) in the same bu¡er. Bound material was eluted with
column bu¡er containing 1 M NaCl. N7,N8-(Dihydroxy-1,2-cyclohex-
ylidene) arginine (DHCH-Arg-) and aminoacetylated derivatives of
isolated PDC-109 (V1 mg/ml in 50 mM Tris-HCl, 150 mM NaCl,
5 mM EDTA, 0.025% NaN3, pH 7.4) were prepared overnight at
room temperature by reaction with a 6-fold molar excess over arginine
residues of 1,2-cyclohexanedione and a 800-fold molar excess over
lysine residues of acetic anhydride, respectively. The same labelling
protocol was carried out using free PDC-109 in solution. The degree
of derivatisation was assessed by MALDI mass spectrometry.
2.4. Endoproteinase Lys-C peptide mapping and peptide
characterisation
DHCH-Arg-PDC-109 and aminoacetylated PDC-109 derivatives
(5^10 mg/ml in 100 mM Tris-HCl, pH 8.6, 6 M guanidine hydro-
chloride) were reduced with 10% (v/v) L-mercaptoethanol for 2 min
at 100‡C, alkylated with a 4.5-fold molar excess of iodoacetamide
over reducing reagent, dialysed against 100 mM NH4HCO3, pH
8.6, 1 M guanidine hydrochloride, and digested in this bu¡er with
endoproteinase Lys-C (substrate:enzyme ratio of 100:1, w/w) over-
night at 37‡C. Endoproteinase Lys-C peptides of DHCH-PDC-109
(termed R-) and aminoacetylated PDC-109 (termed K-) were sepa-
rated by reversed-phase HPLC (250U4 mm Lichrospher RP100
C18, 5 Wm) eluting at 1 ml/min with a mixture of 0.1% TFA in water
(A) and acetonitrile (B), ¢rst 5 min isocratic (5% B), followed by a
linear gradient of 5^50% in 135 min, and 50^70% B in 20 min. Pep-
tides were subjected to amino acid analysis (after hydrolysis with 6 N
HCl, 18 h, 110‡C) using a Pharmacia-LKB AlphaPlus instrument,
N-terminal sequencing (using an Applied Biosystems Procise instru-
ment), and their mass was determined by electrospray ionisation mass
spectrometry using an Sciex API III LC/MS/MS triple quadrupole
mass spectrometer.
3. Results and discussion
3.1. Correlation between the heparin-binding capability and the
quaternary structure of PDC-109
Initially, we sought to characterise the heparin-binding re-
gion of PDC-109 using the approach employed for mapping
the heparin-binding domain of boar spermadhesins [23]. Thus,
PDC-109 was bound to a heparin-Sepharose column and the
conjugated protein was proteolytically degraded overnight.
The rationale behind this approach is that those regions in-
teracting with heparin are protected from proteolysis and will
be recovered in the a⁄nity matrix-bound fraction. However,
using various enzymes displaying diverse cleavage speci¢cities
(K-chymotrypsin, elastase, subtilisin, endoproteinase Glu-C),
we always obtained non-heparin-bound peptides and intact
PDC-109 bound to the a⁄nity column. This strongly sug-
gested that the heparin-binding ability of PDC-109 was de-
pendent on a polypeptide conformation which is only retained
by the native protein. In addition, we noticed that PDC-109
could be eluted from heparin-Sepharose by including in the
column bu¡er NaCl, CaCl2, EDTA, or oPC (Fig. 1). The
concentration of each of these solutes needed for the quanti-
tative elution of PDC-109 from the a⁄nity column was the
same concentration which caused oligomer dissociation of
polydisperse PDC-109 molecules [13]. Thus, the PDC-109
peaks obtained with the di¡erent eluents had maxima centred
at 190 mM NaCl, 48 mM CaCl2, 39 mM EDTA, and 18 mM
oPC (Fig. 1). At these concentrations of solutes, the average
molecular mass of PDC-109, determined by equilibrium sed-
imentation at room (20^22‡C) temperature, was decreased
from 70 kDa to 47, 45, 19, and 20 kDa, respectively [13].
These results indicated a correlation between the aggregation
state of PDC-109 and its heparin-binding a⁄nity, suggesting
that the minimal size of the heparin-binding PDC-109 oligom-
er may display a tetrameric or greater quaternary structure.
Moreover, PDC-109 did not bind to the heparin-Sepharose
column when the chromatography was carried out at 36‡C.
In a previous study we reported that PDC-109 displayed two
calorimetric transition at 36‡C and 55‡C. The 36‡C melting
transition was assigned to the dissociation of the 70-kDa
PDC-109 oligomer [13], which further supports our hypothesis
that the heparin-binding region of PDC-109 is conformational
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Fig. 1. Elution patterns of PDC-109 from a heparin-Sepharose col-
umn as a function of the solute concentration in the elution bu¡er:
E, ortho-phosphorylcholine; a, EDTA; b, CaCl2 ; and R, NaCl.
J.J. Calvete et al./FEBS Letters 444 (1999) 260^264 261
and dependent on the quaternary arrangement of more than
four PDC-109 monomers.
3.2. Mapping the heparin-binding site by selective chemical
modi¢cation
For the identi¢cation of amino acid residues presumably
forming part of the heparin-binding region of quaternary
structure-intact PDC-109 oligomers, we chose an indirect ap-
proach. Isolated PDC-109 was bound at room temperature to
a heparin-Sepharose column and the accessible amino groups
or arginine residues of the bound protein were alternatively
labelled by reaction with acetic anhydride (AcA) or 1,2-cyclo-
hexanedione (CHD). We argued that those lysine and arginine
residues involved in binding heparin will be essentially pro-
tected by the ligand from chemical labelling and will be iden-
ti¢ed by peptide mapping and mass spectrometric character-
isation as unmodi¢ed amino acids. The same amino group-
and arginine-modi¢cation protocols were carried out with free
protein in solution to assess whether the failure to modify a
particular residue could be attributed to a ligand protection
e¡ect or might be due to protein structural constraints. A
similar approach has been successfully applied for mapping
the heparin-binding site of mucus proteinase inhibitor [24].
The molecular mass of free PDC-109 aminoacetylated with
a 800-fold molar excess over lysine residues was 13 174 þ 11
Da, which may correspond to non-glycosylated PDC-109
modi¢ed by nine acetyl moieties (mass increase of 42 Da
per acetylated amino group; calculated isotope-averaged mo-
lecular mass of 13 167 Da). Since PDC-109 contains a free N-
terminal K-amino group and seven lysine O-amino groups
(Fig. 2), the result indicated that all lysine residues were sol-
vent-exposed and that additional acetylation took place at the
reagent concentration used. On the other hand, treatment of
free PDC-109 with a 6-fold molar excess of 1,2-cyclohexane-
dione over arginine residues yielded a modi¢ed protein sample
with molecular masses of 13 235 þ 14 Da and 13 905 þ 6 Da.
These molecular masses were assigned to non-glycosylated
and glycosylated PDC-109 molecules each containing four
DHCH-Arg residues (mass increase of 112 Da per DHCH-
Arg [25] ; calculated isotope-averaged molecular masses of
13 244 Da and 13 899 Da, respectively). This result clearly
indicated that four out of ¢ve arginine residues of PDC-109
(Fig. 1) were accessible to form DHCH-Arg derivatives.
Columns containing 5 mg of PDC-109 bound to heparin-
Sepharose were incubated with a continuous £ow of column
bu¡er containing either a 800-fold molar excess of acetic an-
hydride over lysine residues or a 6-fold molar excess of 1,2-
cyclohexanedione over arginine residues. After washing, the
protein was eluted, dialysed, degraded with endoproteinase
Lys-C, and the resulting peptides were isolated by reversed-
phase HPLC and characterised by amino acid analysis and
mass spectrometry (Fig. 2). CHD-treated PDC-109 peptide
R26 displayed three ions at 3955, 4320, and 4611 Da, which
corresponded to S-carbamoylmethylated (CM) polypeptide
1^34 non-glycosylated (Mcalc : 3956 Da), glycosylated with
GalNAcL(1-3)-Gal [21] (Mcalc : 4321 Da), and glycosylated
with the trisaccharide GalNAcL(1-3)-GalK(2-3)-Neu5Ac [22]
(Mcalc : 4612 Da), respectively. Peptides R28 and R29 showed
in addition to the ions of K26 an ion at 4180 Da, which was
assigned to CM-(1^33) with two DHCH-Arg residues. CHD-
treated PDC-109 peptides R38a (3056 Da), R38b (4581 Da),
R5 (1176 Da), R6 (676 Da) and R10 (547 Da) corresponded
to CM polypeptides 34^59, 37^73, 60^68, 103^107 and 103^
106 with unmodi¢ed arginine residues 57, 64, and 104. These
results showed that only the N-terminal arginines residues 30
and 32 (Fig. 2) were modi¢ed by 1,2-cyclohexanedione.
Characterisation of endoLys-C degradation peptides from
aminoacetylated PDC-109 identi¢ed major peptide K20
(M+3 = 1538 Da, M = 4611 Da) as non-modi¢ed residues
1^34 with threonine 11 O-glycosylated with the trisaccharide
NeuAc-Gal-GalNAc (Fig. 2). Peptide K32 (3055 Da), which
corresponded to the carboxymethylated polypeptide 35^59
(Fig. 2), was produced by cleavage after Lys33 further indicat-
ing that this residue was not acetylated. Peptide K3 (1174 Da)
was identi¢ed as non-modi¢ed polypeptide stretch 60^68
showing that Lys68 was not modi¢ed. Comparing peptides
K1 (930 Da) and K29a (802 Da), which were characterised
as non-acetylated polypeptides 79^85 and 80^85, with pep-
tides K15 (3264 Da, residues 75^100 including aminoacetyl-
ated lysines 78, 79, and 85), and K30 (4208 Da) encompassing
residues 75^108 with aminoacetylated lysine residues 78, 79,
85, and 103, also indicated that modi¢cation of lysine residues
78 and 79 was partial. The ratio of non-modi¢ed to modi¢ed
residue was estimated from the height of the HPLC chromato-
gram to be roughly equimolar. Peptide K9 corresponded to
residues 97^104 including aminoacetylated lysine 102, and
peptide K20 (3458 Da) was identi¢ed as residues 80^106
with aminoacetylated Lys85. However, the fact that minor
peptides K31 (86^93, 998 Da) and K5 (95^102, 923 Da)
were produced by cleavage after lysine residues 85 and 102,
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Fig. 2. Identi¢cation of reversed-phase HPLC-puri¢ed endoprotein-
ase Lys-C-derived peptides of PDC-109 eluted from a heparin-Seph-
arose column after incubation with acetic anhydride (K) or 1,2-cy-
clohexanedione (R-). Disulphide bonds were reduced and cysteine
residues were carboxymethylated before proteolysis. Molecular
masses determined by electrospray ionisation mass spectrometry are
shown in parentheses. Peptides containing aminoacetylated (Ac)
groups and DHCH-Arg residues are indicated.
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respectively, also indicated that acetylation of these residues
was partial (40^50%). Finally, lysine 108 was found as its
aminoacetylated derivative in peptide K29b (residues 103^
109, 1042 Da) (Fig. 2).
As a whole, the results of selective chemical modi¢cation
indicate that six basic residues (Lys34, Arg57, Lys59, Arg64,
Lys68, and Arg104) were protected from reaction with acetic
anhydride and 1,2-cyclohexanedione in heparin-bound PDC-
109 oligomers. The lysine residues may be truly shielded by
bound heparin because all lysine residues of free PDC-109
were labelled by acetic anhydride. On the other hand, since
only four out of ¢ve PDC-109 arginines were accessible to 1,2-
cyclohexanedione labelling, at least two of the three non-
modi¢ed arginine residues of heparin-bound PDC-109 may
reside within the heparin-binding region. The third non-la-
belled arginine residue could form part of the intersubunit
surface.
3.3. On the topology of the heparin-binding region of PDC-109
oligomers
The three-dimensional structure of full-length PDC-109 has
not been solved. However, several groups have reported the
NMR solution structure of individual Fn type II modules,
including PDC-109 domain b (residues 65^109) [26] and the
¢rst and second human ¢bronectin type II modules [27,28]
(Fig. 3). These studies showed that each FnII domain contains
two double-stranded antiparallel L-sheets, oriented almost
perpendicular to each other, which enclose a cluster of con-
served solvent-exposed aromatic residues possibly involved in
the binding of hydrophobic ligands. In each of these struc-
tures residues topologically equivalent to PDC-109 Arg57
(Arg104) and Lys59 are solvent-exposed and located around
L-strand D on the same face of the domain, and Arg64 and
Lys68 are located in the polypeptide stretch between domains
a and b (Fig. 3). The side chain of Lys68 is likely also to form
part of the same cluster of positively charged residues (Fig. 4).
However, lysine 11, which is topologically equivalent of Lys34
(Fig. 3), is oriented towards the opposite site of the domain. It
is possible that this residue forms part of another cluster of
basic residues in full-length PDC-109 or PDC-109 oligomers.
Alternatively, Lys34 may be protected from chemical modi¢-
cation because it is hidden in the oligomeric association of
PDC-109.
The arrangement of the conformational and quaternary
structure-dependent heparin-binding site of PDC-109 resem-
bles the topology of glycosaminoglycan-binding sites of other
heparin-binding proteins, which are typically extended clusters
or bands of positively charged amino acids distributed along
the surface of the protein, or in a shallow groove [29]. Resi-
dues important for binding heparin are often remote in the
amino acid sequence but are brought together in the folded
protein. Moreover, many heparin-binding proteins display
non-contiguous cationic clusters distant from each other by
16^24 Aî . The fact that oligomeric, but not monomeric, PDC-
109 possesses heparin-binding activity indicates that the PDC-
109 monomer lacks the strategically positioned cationic resi-
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Fig. 4. Stereo drawing of the K-carbon backbone of the PDC-109 domain b structure showing the relative orientation of residues Lys68, Lys79,
Arg104, and Lys107. The latter three residues are topologically equivalent to domain b residues Lys34, Arg57 and Lys59, respectively (Fig. 3),
which are shielded from cheminal modi¢cation in heparin-bound PDC-109 oligomers.
Fig. 3. Alignment of the amino acid sequences of the ¢bronectin type II (FnII) domains a and b of PDC-109 and the ¢rst and second FnII
modules of human ¢bronectin (labelled PDC109-a, PDC109-b, FN-1F2, and FN-2F2, respectively). The four L-strands of the NMR solution
structures of the latter three FnII domains [26^28] are labelled A^D. The six basic residues of PDC-109 protected by bound heparin from
chemical modi¢cation are identi¢ed with asterisks.
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dues that are necessary for tight binding to heparin. A similar
example is platelet factor 4, where the clustering of four lysine
residues contributed by each monomer is enhanced through
self-association of the protein to form dimers and tetramers
with progressively higher a⁄nity for heparin [30].
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